Roflumilast for asthma and chronic obstructive pulmonary disease

Cowan C
Record ID 32005001210
English, French
Authors' objectives:

The aim of this report is to review the available information on the use of roflumilast (Daxas, manufactured by ALTANA Pharma Inc.), an inhibitor of phosphodiesterase-IV (PDE4), to suppress the inflammatory activity in many airway cells implicated in the pathogenesis of asthma and chronic obstructive pulmonary disease (COPD).

Authors' results and conclusions: In clinical trials, roflumilast produced significant improvements in FEV1 (forced expiratory volume in one second) and PEF (peak expiratory flow) compared with low-dose inhaled beclomethasone in asthma patients, and compared with placebo in COPD patients. Roflumilast reduced the use of rescue medication in both populations. COPD patients on roflumilast experienced fewer exacerbations. The most common adverse effects reported in roflumilast trials were diarrhea, nausea, headache, and abdominal pain.
Authors' recommendations: Evidence is only available in non-peer-reviewed format abstracts. Most of the measures used are markers of clinical effects as opposed to clinical outcomes. More studies are needed to determine the role of roflumilast in the treatment of asthma and COPD.
Authors' methods: Overview
Project Status: Completed
URL for project:
Year Published: 2005
URL for published report: n/a
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Benzamides
  • Aminopyridines
  • Asthma
  • Pulmonary Disease, Chronic Obstructive
  • Cyclopropanes
  • Phosphodiesterase 4 Inhibitors
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Coordinating Office for Health Technology Assessment(CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.